有活動性發燒感染或呼吸道疾病（包括未治療的活動性結核）；應考慮延後接種疫苗
Active febrile infection or respiratory illness, including active untreated tuberculosis; consider deferring vaccination.
正接受化療或放療者；除非益處大於不良反應的風險，否則不得在至少3個月內接種活疫苗
Concomitant chemotherapy or radiation therapy; live vaccine should not be administered for at least 3 months unless benefit outweighs risk of adverse reactions.
對疫苗成分嚴重過敏禁止使用
Severe allergic reaction to any component of the vaccine is contraindicated.
與HIV相關的感染及艾滋病；免疫抑制或免疫缺陷，包括原發性或後天免疫缺陷、白血病、淋巴瘤或其他影響淋巴系統或骨髓的惡性腫瘤病史
HIV-associated infections and AIDS；Immunosuppression or immunodeficiency, including a history of primary or acquired immunodeficiency or leukemia, lymphoma, or other malignant neoplasms affecting the lymphatic system or bone marrow.
孕婦；注射後四週內應避免懷孕
Pregnancy; Avoid pregnancy within 4 weeks after vaccination.
接受一般肌肉注射免疫球蛋白治療或B型肝炎免疫球蛋白者，宜間隔3個月後再接種水痘疫苗
Patients treated with standard intramuscular immunoglobulin or hepatitis B immunoglobulin should delay varicella vaccination for at least 3 months.
麻疹個案接觸者，如施打預防性肌肉注射免疫球蛋白，則應間隔6個月以上再接種水痘疫苗
For measles case contacts receiving prophylactic intramuscular immunoglobulin, delay varicella vaccination for at least 6 months.
輸過血或接受靜脈注射血液製品者，宜間隔6個月後再接種水痘疫苗
Patients who have received blood transfusion or intravenous blood products should delay varicella vaccination for at least 6 months.
曾注射高劑量靜脈注射免疫球蛋白 (≥1g/kg)者，須間隔十一個月後才能注射本品
Patients who have received high-dose intravenous immunoglobulin (≥1g/kg) delay vaccination with this product for 11 months.
任何免疫性球蛋白包括VZIG均不可在注射VARIVAX後二個月內使用，除非其醫療之好處超過注射疫苗的利益
No immune globulin, including VZIG, should be administered within 2 months after VARIVAX unless the medical benefit outweighs the vaccination benefits.
Local: Injection site reaction (19% to 33%)
Miscellaneous: Fever (10% to 15%)
1% to 10%:
Central nervous system: Chills, disturbed sleep, fatigue, headache, irritability, malaise, nervousness Dermatologic: Varicella-like rash (1% to 6%), rash at injection site (varicella-like; 1% to 3%), contact dermatitis, dermatitis, diaper rash, eczema, miliaria, pruritus, urticaria, xeroderma
Gastrointestinal: Abdominal pain, constipation, decreased appetite, diarrhea, nausea, period of tooth development, vomiting
Genitourinary: Herpes labialis
Hematologic & oncologic: Lymphadenopathy
Hypersensitivity: Hypersensitivity reaction
Neuromuscular & skeletal: Arthralgia, myalgia, neck stiffness
Otic: Otitis
Respiratory: Cough, respiratory tract disease (lower/upper)(UTD)
每次肌肉或皮下注射劑量為0.5 mL。
Each dose is 0.5 mL administered intramuscularly or subcutaneously.
12個月大至12歲的兒童若施打第二劑時，兩劑之間應間隔至少3個月。
For children aged 12 months to 12 years, at least 3 months should elapse between the two doses if administering the second dose.
13歲以上的青少年及成人須施打兩劑，兩劑之間應間隔4到8週。
Adolescents aged 13 years and older, as well as adults, should receive two doses with an interval of 4 to 8 weeks between the doses.
(13 years or older) 0.5 mL/dose subQ for 2 doses; allow at least 4 weeks to elapse between doses
(12 months to 6 years) Routine vaccination, administer first dose at 12 to 15 months and second dose at 4 to 6 years or before age 4 years if at least 3 months have passed since first dose; vaccine may be accepted as valid if second dose administered at least 4 weeks after the first dose
(7 to 12 years without evidence of immunity) Catch-up vaccination, administer 2 doses with a minimum interval of 3 months between doses; vaccine may be accepted as valid if second dose is administered at least 4 weeks after the first dose
(13 years or older without evidence of immunity) Catch-up vaccination, administer 2 doses with a minimum interval of 4 weeks between doses.